Bailey Roberts

155 timestamped statements across 4 topics — auto-found in recorded discussions, each timestamp jumps to the exact moment.

Sarcoma (Ewing/Rhabdo) · guest expert

Featured statements

▶ Ep 1 · 5:39
Extracellular vesicles can cause metastatic spread and therefore be a therapeutic target for osteosarcoma metastasis.
quote · Metastatic Osteosarcoma
▶ Ep 1 · 1:32
Extracellular vesicles or EVs are small nanoparticles released from all cells.
quote · Metastatic Osteosarcoma
▶ Ep 3 · 1:04
Osteosarcoma is a malignant pediatric tumor of the bone.
quote · Osteosarcoma
▶ Ep 3 · 7:10
Surgically removing the primary tumor is the current standard of care for osteosarcoma
guideline · Osteosarcoma
▶ Ep 463 · 7:40
The differences in EVs by cell type have more to do with the contents inside of them than the targets on them, which makes them difficult to target as far as treatment
clinical · Pediatric Oncology
▶ Ep 463 · 6:27
All cells in the body release EVs, so we can't just generally target EVs and hope to decrease the establishment of a pre-metastatic niche
clinical · Pediatric Oncology

Nothing matches these filters — clear the search or widen the filters.

Bailey's statements about Metastatic Osteosarcoma 31 statements

Open the Metastatic Osteosarcoma collection →

Bailey Roberts, MD - Best of the Best in Pediatric Surgery 2024

▶ Ep 1 · 1:04
quote Osteosarcoma is a malignant pediatric tumor of the bone. ↗
▶ Ep 1 · 1:08
epidemiological Osteosarcoma most commonly affects adolescents and young adults ↗
▶ Ep 1 · 1:11
epidemiological Gross metastasis at the time of diagnosis is present about 20% of the time in osteosarcoma ↗
▶ Ep 1 · 1:11
clinical The most common site of metastasis in osteosarcoma is in the lung ↗
▶ Ep 1 · 1:19
epidemiological Overall survival in osteosarcoma worsens from 80% to about 20% for metastatic disease ↗
▶ Ep 1 · 1:25
clinical Recurrence is very common in osteosarcoma, and the most common site of recurrence is in the lungs ↗
▶ Ep 1 · 1:32
quote Extracellular vesicles or EVs are small nanoparticles released from all cells. ↗
▶ Ep 1 · 1:38
clinical Extracellular vesicles are carriers of amino acids, proteins, mRNA or other forms of cellular communication ↗
▶ Ep 1 · 1:45
clinical EV content is unique and specific to the cells that released it, and therefore can be traced back to the cell type ↗
▶ Ep 1 · 1:52
clinical EVs are involved in the metastatic cascade and implicated as potential markers for disease diagnosis and staging ↗
▶ Ep 1 · 1:59
clinical EVs have been shown to change fibroblasts, inhibit T cell activity, and are involved in establishing a pre-metastatic niche ↗
▶ Ep 1 · 2:14
quote The aim of our study was to determine if extracellular vesicles from osteosarcoma can establish a pre-metastatic niche and increase pulmonary metastasis in a mirroring model of osteosarcoma. ↗
▶ Ep 1 · 2:31
clinical K12 is a spontaneous osteosarcoma with low metastatic capability ↗
▶ Ep 1 · 2:35
clinical K7M2 is a highly metastatic osteosarcoma derived from a spontaneous osteosarcoma that went through two reiterations of harvesting spontaneous lung metastases and reimplanting them into the mouse ↗
▶ Ep 1 · 2:57
clinical The K7M2 cell line is more aggressive and causes death at a much higher rate than K12 ↗
▶ Ep 1 · 3:59
clinical Pre-education with K7M2 EVs drastically increases the metastatic burden in the lungs of mice with K7M2 tumors ↗
▶ Ep 1 · 4:18
clinical Pre-education with K7M2 EVs increased the overall mortality during the five-week study period in mice with K7M2 tumors ↗
▶ Ep 1 · 4:44
clinical K7M2 EV education led to increased metastatic burden in mice with K12 tumors ↗
▶ Ep 1 · 5:01
clinical Pre-education with highly metastatic cell line EVs increases the metastasis seen in a normally low metastatic tumor ↗
▶ Ep 1 · 5:09
clinical No mice with K12 tumors died in the study period ↗
▶ Ep 1 · 5:14
clinical Extracellular vesicles delivered prior to tumor implantation from highly metastatic K7M2 increase the metastatic burden of K7M2 tumors ↗
▶ Ep 1 · 5:24
clinical Increased metastatic burden from extracellular vesicles decreases overall survival ↗
▶ Ep 1 · 5:30
clinical Extracellular vesicles from highly metastatic K7M2 increase the metastatic burden of less metastatic K12 tumors ↗
▶ Ep 1 · 5:39
quote Extracellular vesicles can cause metastatic spread and therefore be a therapeutic target for osteosarcoma metastasis. ↗
▶ Ep 1 · 6:27
clinical All cells in the body release EVs, so we can't just generally target EVs and hope to decrease the establishment of a pre-metastatic niche ↗
▶ Ep 1 · 6:48
clinical IRF5 is a molecule being explored as a potential immunotherapy target in osteosarcoma EVs ↗
▶ Ep 1 · 7:10
quote I don't think that it could treat the primary tumor as well as surgically removing it, which is, um, the current standard of care. ↗
▶ Ep 1 · 7:10
guideline Surgically removing the primary tumor is the current standard of care for osteosarcoma ↗
▶ Ep 1 · 7:31
clinical There are certain membrane EV markers, but they're shared by all types of EVs ↗
▶ Ep 1 · 7:40
clinical The differences in EVs by cell type have more to do with the contents inside of them than the targets on them, which makes them difficult to target as far as treatment ↗
▶ Ep 1 · 7:57
clinical Studies in dogs have shown ability to take serum of dogs with osteosarcoma and determine their likelihood of metastasis based on the EVs ↗
Bailey's statements about Osteosarcoma 31 statements

Open the Osteosarcoma collection →

Bailey Roberts, MD - Best of the Best in Pediatric Surgery 2024

▶ Ep 3 · 1:04
quote Osteosarcoma is a malignant pediatric tumor of the bone. ↗
▶ Ep 3 · 1:08
epidemiological Osteosarcoma most commonly affects adolescents and young adults ↗
▶ Ep 3 · 1:11
epidemiological Gross metastasis at the time of diagnosis is present about 20% of the time in osteosarcoma ↗
▶ Ep 3 · 1:11
clinical The most common site of metastasis in osteosarcoma is in the lung ↗
▶ Ep 3 · 1:19
epidemiological Overall survival in osteosarcoma worsens from 80% to about 20% for metastatic disease ↗
▶ Ep 3 · 1:25
clinical Recurrence is very common in osteosarcoma, and the most common site of recurrence is in the lungs ↗
▶ Ep 3 · 1:32
quote Extracellular vesicles or EVs are small nanoparticles released from all cells. ↗
▶ Ep 3 · 1:38
clinical Extracellular vesicles are carriers of amino acids, proteins, mRNA or other forms of cellular communication ↗
▶ Ep 3 · 1:45
clinical EV content is unique and specific to the cells that released it, and therefore can be traced back to the cell type ↗
▶ Ep 3 · 1:52
clinical EVs are involved in the metastatic cascade and implicated as potential markers for disease diagnosis and staging ↗
▶ Ep 3 · 1:59
clinical EVs have been shown to change fibroblasts, inhibit T cell activity, and are involved in establishing a pre-metastatic niche ↗
▶ Ep 3 · 2:14
quote The aim of our study was to determine if extracellular vesicles from osteosarcoma can establish a pre-metastatic niche and increase pulmonary metastasis in a mirroring model of osteosarcoma. ↗
▶ Ep 3 · 2:31
clinical K12 is a spontaneous osteosarcoma with low metastatic capability ↗
▶ Ep 3 · 2:35
clinical K7M2 is a highly metastatic osteosarcoma derived from a spontaneous osteosarcoma that went through two reiterations of harvesting spontaneous lung metastases and reimplanting them into the mouse ↗
▶ Ep 3 · 2:57
clinical The K7M2 cell line is more aggressive and causes death at a much higher rate than K12 ↗
▶ Ep 3 · 3:59
clinical Pre-education with K7M2 EVs drastically increases the metastatic burden in the lungs of mice with K7M2 tumors ↗
▶ Ep 3 · 4:18
clinical Pre-education with K7M2 EVs increased the overall mortality during the five-week study period in mice with K7M2 tumors ↗
▶ Ep 3 · 4:44
clinical K7M2 EV education led to increased metastatic burden in mice with K12 tumors ↗
▶ Ep 3 · 5:01
clinical Pre-education with highly metastatic cell line EVs increases the metastasis seen in a normally low metastatic tumor ↗
▶ Ep 3 · 5:09
clinical No mice with K12 tumors died in the study period ↗
▶ Ep 3 · 5:14
clinical Extracellular vesicles delivered prior to tumor implantation from highly metastatic K7M2 increase the metastatic burden of K7M2 tumors ↗
▶ Ep 3 · 5:24
clinical Increased metastatic burden from extracellular vesicles decreases overall survival ↗
▶ Ep 3 · 5:30
clinical Extracellular vesicles from highly metastatic K7M2 increase the metastatic burden of less metastatic K12 tumors ↗
▶ Ep 3 · 5:39
quote Extracellular vesicles can cause metastatic spread and therefore be a therapeutic target for osteosarcoma metastasis. ↗
▶ Ep 3 · 6:27
clinical All cells in the body release EVs, so we can't just generally target EVs and hope to decrease the establishment of a pre-metastatic niche ↗
▶ Ep 3 · 6:48
clinical IRF5 is a molecule being explored as a potential immunotherapy target in osteosarcoma EVs ↗
▶ Ep 3 · 7:10
quote I don't think that it could treat the primary tumor as well as surgically removing it, which is, um, the current standard of care. ↗
▶ Ep 3 · 7:10
guideline Surgically removing the primary tumor is the current standard of care for osteosarcoma ↗
▶ Ep 3 · 7:31
clinical There are certain membrane EV markers, but they're shared by all types of EVs ↗
▶ Ep 3 · 7:40
clinical The differences in EVs by cell type have more to do with the contents inside of them than the targets on them, which makes them difficult to target as far as treatment ↗
▶ Ep 3 · 7:57
clinical Studies in dogs have shown ability to take serum of dogs with osteosarcoma and determine their likelihood of metastasis based on the EVs ↗
Bailey's statements about Pediatric Oncology 31 statements

Open the Pediatric Oncology collection →

Bailey Roberts, MD - Best of the Best in Pediatric Surgery 2024

▶ Ep 463 · 1:04
quote Osteosarcoma is a malignant pediatric tumor of the bone. ↗
▶ Ep 463 · 1:08
epidemiological Osteosarcoma most commonly affects adolescents and young adults ↗
▶ Ep 463 · 1:11
clinical The most common site of metastasis in osteosarcoma is in the lung ↗
▶ Ep 463 · 1:11
epidemiological Gross metastasis at the time of diagnosis is present about 20% of the time in osteosarcoma ↗
▶ Ep 463 · 1:19
epidemiological Overall survival in osteosarcoma worsens from 80% to about 20% for metastatic disease ↗
▶ Ep 463 · 1:25
clinical Recurrence is very common in osteosarcoma, and the most common site of recurrence is in the lungs ↗
▶ Ep 463 · 1:32
quote Extracellular vesicles or EVs are small nanoparticles released from all cells. ↗
▶ Ep 463 · 1:38
clinical Extracellular vesicles are carriers of amino acids, proteins, mRNA or other forms of cellular communication ↗
▶ Ep 463 · 1:45
clinical EV content is unique and specific to the cells that released it, and therefore can be traced back to the cell type ↗
▶ Ep 463 · 1:52
clinical EVs are involved in the metastatic cascade and implicated as potential markers for disease diagnosis and staging ↗
▶ Ep 463 · 1:59
clinical EVs have been shown to change fibroblasts, inhibit T cell activity, and are involved in establishing a pre-metastatic niche ↗
▶ Ep 463 · 2:14
quote The aim of our study was to determine if extracellular vesicles from osteosarcoma can establish a pre-metastatic niche and increase pulmonary metastasis in a mirroring model of osteosarcoma. ↗
▶ Ep 463 · 2:31
clinical K12 is a spontaneous osteosarcoma with low metastatic capability ↗
▶ Ep 463 · 2:35
clinical K7M2 is a highly metastatic osteosarcoma derived from a spontaneous osteosarcoma that went through two reiterations of harvesting spontaneous lung metastases and reimplanting them into the mouse ↗
▶ Ep 463 · 2:57
clinical The K7M2 cell line is more aggressive and causes death at a much higher rate than K12 ↗
▶ Ep 463 · 3:59
clinical Pre-education with K7M2 EVs drastically increases the metastatic burden in the lungs of mice with K7M2 tumors ↗
▶ Ep 463 · 4:18
clinical Pre-education with K7M2 EVs increased the overall mortality during the five-week study period in mice with K7M2 tumors ↗
▶ Ep 463 · 4:44
clinical K7M2 EV education led to increased metastatic burden in mice with K12 tumors ↗
▶ Ep 463 · 5:01
clinical Pre-education with highly metastatic cell line EVs increases the metastasis seen in a normally low metastatic tumor ↗
▶ Ep 463 · 5:09
clinical No mice with K12 tumors died in the study period ↗
▶ Ep 463 · 5:14
clinical Extracellular vesicles delivered prior to tumor implantation from highly metastatic K7M2 increase the metastatic burden of K7M2 tumors ↗
▶ Ep 463 · 5:24
clinical Increased metastatic burden from extracellular vesicles decreases overall survival ↗
▶ Ep 463 · 5:30
clinical Extracellular vesicles from highly metastatic K7M2 increase the metastatic burden of less metastatic K12 tumors ↗
▶ Ep 463 · 5:39
quote Extracellular vesicles can cause metastatic spread and therefore be a therapeutic target for osteosarcoma metastasis. ↗
▶ Ep 463 · 6:27
clinical All cells in the body release EVs, so we can't just generally target EVs and hope to decrease the establishment of a pre-metastatic niche ↗
▶ Ep 463 · 6:48
clinical IRF5 is a molecule being explored as a potential immunotherapy target in osteosarcoma EVs ↗
▶ Ep 463 · 7:10
quote I don't think that it could treat the primary tumor as well as surgically removing it, which is, um, the current standard of care. ↗
▶ Ep 463 · 7:10
guideline Surgically removing the primary tumor is the current standard of care for osteosarcoma ↗
▶ Ep 463 · 7:31
clinical There are certain membrane EV markers, but they're shared by all types of EVs ↗
▶ Ep 463 · 7:40
clinical The differences in EVs by cell type have more to do with the contents inside of them than the targets on them, which makes them difficult to target as far as treatment ↗
▶ Ep 463 · 7:57
clinical Studies in dogs have shown ability to take serum of dogs with osteosarcoma and determine their likelihood of metastasis based on the EVs ↗
Bailey's statements about Sarcoma (Ewing/Rhabdo) 62 statements

Open the Sarcoma (Ewing/Rhabdo) collection →

Bailey Roberts, MD - Best of the Best in Pediatric Surgery 2024

▶ Ep 20 · 1:04
quote Osteosarcoma is a malignant pediatric tumor of the bone. ↗
▶ Ep 20 · 1:04
quote Osteosarcoma is a malignant pediatric tumor of the bone. ↗
▶ Ep 20 · 1:08
epidemiological Osteosarcoma most commonly affects adolescents and young adults ↗
▶ Ep 20 · 1:08
epidemiological Osteosarcoma most commonly affects adolescents and young adults ↗
▶ Ep 20 · 1:11
clinical The most common site of metastasis in osteosarcoma is in the lung ↗
▶ Ep 20 · 1:11
epidemiological Gross metastasis at the time of diagnosis is present about 20% of the time in osteosarcoma ↗
▶ Ep 20 · 1:11
clinical The most common site of metastasis in osteosarcoma is in the lung ↗
▶ Ep 20 · 1:11
epidemiological Gross metastasis at the time of diagnosis is present about 20% of the time in osteosarcoma ↗
▶ Ep 20 · 1:19
epidemiological Overall survival in osteosarcoma worsens from 80% to about 20% for metastatic disease ↗
▶ Ep 20 · 1:19
epidemiological Overall survival in osteosarcoma worsens from 80% to about 20% for metastatic disease ↗
▶ Ep 20 · 1:25
clinical Recurrence is very common in osteosarcoma, and the most common site of recurrence is in the lungs ↗
▶ Ep 20 · 1:25
clinical Recurrence is very common in osteosarcoma, and the most common site of recurrence is in the lungs ↗
▶ Ep 20 · 1:32
quote Extracellular vesicles or EVs are small nanoparticles released from all cells. ↗
▶ Ep 20 · 1:32
quote Extracellular vesicles or EVs are small nanoparticles released from all cells. ↗
▶ Ep 20 · 1:38
clinical Extracellular vesicles are carriers of amino acids, proteins, mRNA or other forms of cellular communication ↗
▶ Ep 20 · 1:38
clinical Extracellular vesicles are carriers of amino acids, proteins, mRNA or other forms of cellular communication ↗
▶ Ep 20 · 1:45
clinical EV content is unique and specific to the cells that released it, and therefore can be traced back to the cell type ↗
▶ Ep 20 · 1:45
clinical EV content is unique and specific to the cells that released it, and therefore can be traced back to the cell type ↗
▶ Ep 20 · 1:52
clinical EVs are involved in the metastatic cascade and implicated as potential markers for disease diagnosis and staging ↗
▶ Ep 20 · 1:52
clinical EVs are involved in the metastatic cascade and implicated as potential markers for disease diagnosis and staging ↗
▶ Ep 20 · 1:59
clinical EVs have been shown to change fibroblasts, inhibit T cell activity, and are involved in establishing a pre-metastatic niche ↗
▶ Ep 20 · 1:59
clinical EVs have been shown to change fibroblasts, inhibit T cell activity, and are involved in establishing a pre-metastatic niche ↗
▶ Ep 20 · 2:14
quote The aim of our study was to determine if extracellular vesicles from osteosarcoma can establish a pre-metastatic niche and increase pulmonary metastasis in a mirroring model of osteosarcoma. ↗
▶ Ep 20 · 2:14
quote The aim of our study was to determine if extracellular vesicles from osteosarcoma can establish a pre-metastatic niche and increase pulmonary metastasis in a mirroring model of osteosarcoma. ↗
▶ Ep 20 · 2:31
clinical K12 is a spontaneous osteosarcoma with low metastatic capability ↗
▶ Ep 20 · 2:31
clinical K12 is a spontaneous osteosarcoma with low metastatic capability ↗
▶ Ep 20 · 2:35
clinical K7M2 is a highly metastatic osteosarcoma derived from a spontaneous osteosarcoma that went through two reiterations of harvesting spontaneous lung metastases and reimplanting them into the mouse ↗
▶ Ep 20 · 2:35
clinical K7M2 is a highly metastatic osteosarcoma derived from a spontaneous osteosarcoma that went through two reiterations of harvesting spontaneous lung metastases and reimplanting them into the mouse ↗
▶ Ep 20 · 2:57
clinical The K7M2 cell line is more aggressive and causes death at a much higher rate than K12 ↗
▶ Ep 20 · 2:57
clinical The K7M2 cell line is more aggressive and causes death at a much higher rate than K12 ↗
▶ Ep 20 · 3:59
clinical Pre-education with K7M2 EVs drastically increases the metastatic burden in the lungs of mice with K7M2 tumors ↗
▶ Ep 20 · 3:59
clinical Pre-education with K7M2 EVs drastically increases the metastatic burden in the lungs of mice with K7M2 tumors ↗
▶ Ep 20 · 4:18
clinical Pre-education with K7M2 EVs increased the overall mortality during the five-week study period in mice with K7M2 tumors ↗
▶ Ep 20 · 4:18
clinical Pre-education with K7M2 EVs increased the overall mortality during the five-week study period in mice with K7M2 tumors ↗
▶ Ep 20 · 4:44
clinical K7M2 EV education led to increased metastatic burden in mice with K12 tumors ↗
▶ Ep 20 · 4:44
clinical K7M2 EV education led to increased metastatic burden in mice with K12 tumors ↗
▶ Ep 20 · 5:01
clinical Pre-education with highly metastatic cell line EVs increases the metastasis seen in a normally low metastatic tumor ↗
▶ Ep 20 · 5:01
clinical Pre-education with highly metastatic cell line EVs increases the metastasis seen in a normally low metastatic tumor ↗
▶ Ep 20 · 5:09
clinical No mice with K12 tumors died in the study period ↗
▶ Ep 20 · 5:09
clinical No mice with K12 tumors died in the study period ↗
▶ Ep 20 · 5:14
clinical Extracellular vesicles delivered prior to tumor implantation from highly metastatic K7M2 increase the metastatic burden of K7M2 tumors ↗
▶ Ep 20 · 5:14
clinical Extracellular vesicles delivered prior to tumor implantation from highly metastatic K7M2 increase the metastatic burden of K7M2 tumors ↗
▶ Ep 20 · 5:24
clinical Increased metastatic burden from extracellular vesicles decreases overall survival ↗
▶ Ep 20 · 5:24
clinical Increased metastatic burden from extracellular vesicles decreases overall survival ↗
▶ Ep 20 · 5:30
clinical Extracellular vesicles from highly metastatic K7M2 increase the metastatic burden of less metastatic K12 tumors ↗
▶ Ep 20 · 5:30
clinical Extracellular vesicles from highly metastatic K7M2 increase the metastatic burden of less metastatic K12 tumors ↗
▶ Ep 20 · 5:39
quote Extracellular vesicles can cause metastatic spread and therefore be a therapeutic target for osteosarcoma metastasis. ↗
▶ Ep 20 · 5:39
quote Extracellular vesicles can cause metastatic spread and therefore be a therapeutic target for osteosarcoma metastasis. ↗
▶ Ep 20 · 6:27
clinical All cells in the body release EVs, so we can't just generally target EVs and hope to decrease the establishment of a pre-metastatic niche ↗
▶ Ep 20 · 6:27
clinical All cells in the body release EVs, so we can't just generally target EVs and hope to decrease the establishment of a pre-metastatic niche ↗
▶ Ep 20 · 6:48
clinical IRF5 is a molecule being explored as a potential immunotherapy target in osteosarcoma EVs ↗
▶ Ep 20 · 6:48
clinical IRF5 is a molecule being explored as a potential immunotherapy target in osteosarcoma EVs ↗
▶ Ep 20 · 7:10
guideline Surgically removing the primary tumor is the current standard of care for osteosarcoma ↗
▶ Ep 20 · 7:10
quote I don't think that it could treat the primary tumor as well as surgically removing it, which is, um, the current standard of care. ↗
▶ Ep 20 · 7:10
quote I don't think that it could treat the primary tumor as well as surgically removing it, which is, um, the current standard of care. ↗
▶ Ep 20 · 7:10
guideline Surgically removing the primary tumor is the current standard of care for osteosarcoma ↗
▶ Ep 20 · 7:31
clinical There are certain membrane EV markers, but they're shared by all types of EVs ↗
▶ Ep 20 · 7:31
clinical There are certain membrane EV markers, but they're shared by all types of EVs ↗
▶ Ep 20 · 7:40
clinical The differences in EVs by cell type have more to do with the contents inside of them than the targets on them, which makes them difficult to target as far as treatment ↗
▶ Ep 20 · 7:40
clinical The differences in EVs by cell type have more to do with the contents inside of them than the targets on them, which makes them difficult to target as far as treatment ↗
▶ Ep 20 · 7:57
clinical Studies in dogs have shown ability to take serum of dogs with osteosarcoma and determine their likelihood of metastasis based on the EVs ↗
▶ Ep 20 · 7:57
clinical Studies in dogs have shown ability to take serum of dogs with osteosarcoma and determine their likelihood of metastasis based on the EVs ↗